Network meta-analyses: no compensation for weak evidence


7 July 2020 - BMJ publication headed by IQWiG: relevant controlled studies and individual patient data are necessary for informative comparisons of biologics.

Numerous biologics for the treatment of rheumatoid arthritis have been available for several years. What are the advantages and disadvantages of the individual drugs in combination with methotrexate compared with the other biologics? 

This is a question of great practical importance for such a common disease, but it is still difficult to answer – not least because, in most of the studies conducted for drug approvals, no other biologics were used in the comparator arms.

Read IQWiG press release

Michael Wonder

Posted by:

Michael Wonder